Hemab Therapeutics raises $135 million in Series B financing

HealthCap VIII portfolio company Hemab Therapeutics has closed an oversubscribed $135 million Series B financing.

Based in Denmark and Boston, USA, Hemab is a clinical-stage biotechnology company developing the first prophylactic therapeutics for serious, underserved bleeding and thrombotic disorders. Hemab came on the scene in 2020, co-founded by Johan Faber and Søren Bjørn, who until 2018, held leadership positions within hemophilia drug research and development at Danish diabetes care giant Novo Nordisk (NOV: N).

The financing will support Hemab’s scientific and corporate growth plans through 2025, including completion of an ongoing Phase I/II clinical study of lead candidate HMB-001 in Glanzmann thrombasthenia, initiation of pivotal studies, start and completion of Phase I/II clinical evaluation for HMB-VWF in von Willebrand disease, and future pipeline evolution in accordance with the company’s Hemab 1-2-5 strategic guidance - targeting development of five clinical assets by 2025.